Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs)

Purpose This project aimed to survey the clinical characteristics and survivals of hyperprogressive disease (HPD) mediated by immune checkpoint inhibitors (ICIs) in an attempt to explore the potential predictors. Methods After searching PubMed, MEDLINE, Google Scholar and Cochrane Library databases,...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Liu, J. [verfasserIn] Wu, Q. [verfasserIn] Wu, S. [verfasserIn] Xie, X. [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2021

Schlagwörter:	Immune checkpoint inhibitors (ICIs) Hyperprogressive disease (HPD) Predictors Survival analysis

Anmerkung:	© Federación de Sociedades Españolas de Oncología (FESEO) 2021

Übergeordnetes Werk:	Enthalten in: Revista de oncología - Barcelona : Doyma, 2000, 23(2021), 9 vom: 13. Apr., Seite 1782-1793
Übergeordnetes Werk:	volume:23 ; year:2021 ; number:9 ; day:13 ; month:04 ; pages:1782-1793

Links:	Volltext

DOI / URN:	10.1007/s12094-021-02579-9

Katalog-ID:	SPR044656297

Internformat


LEADER	01000caa a22002652 4500
001	SPR044656297
003	DE-627
005	20230519234225.0
007	cr uuu---uuuuu
008	210725s2021 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s12094-021-02579-9 \|2 doi
035			\|a (DE-627)SPR044656297
035			\|a (SPR)s12094-021-02579-9-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q ASE
100	1		\|a Liu, J. \|e verfasserin \|4 aut
245	1	0	\|a Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs)
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © Federación de Sociedades Españolas de Oncología (FESEO) 2021
520			\|a Purpose This project aimed to survey the clinical characteristics and survivals of hyperprogressive disease (HPD) mediated by immune checkpoint inhibitors (ICIs) in an attempt to explore the potential predictors. Methods After searching PubMed, MEDLINE, Google Scholar and Cochrane Library databases, 12 studies incorporating 1766 individuals were enrolled. The data were analyzed with Review manager 5.3 software. Results The results revealed HPD correlated with previous metastatic sites > 2 (OR = 1.86, 95% CI 1.33–2.59, P = 0.0003), liver metastasis (OR = 3.35, 95% CI 2.09–5.35, P < 0.00001), Royal Marsden Hospital (RMH) score ≥ 2 (OR = 2.80, 95% CI 1.85–4.23, P < 0.00001), higher ECOG PS (OR = 1.60, 95% CI 1.13–2.27, P = 0.008) and LDH > upper limits of normal (ULN) (OR = 2.32, 95% CI 1.51–3.58, P = 0.0001). Instead, HPD was unrelated to gender, age, smoking status, PD-L1 expression, therapy, neutrophil-to-lymphocyte ratio, the histology, the status of EGFR, ALK and KRAS in non-small cell lung cancer and HER-2 expression in advanced gastric cancer. Moreover, HPD was evidently correlated with a shorter OS (HR = 2.92, 95% CI 1.79–4.76, P < 0.0001) and PFS (HR = 3.62, 95% CI 2.79–4.68, P < 0.00001). The same phenomena existed in stratified studies based on study regions and tumor types. Conclusions This study demonstrated that HPD was related to the number of prior metastatic sites > 2, liver metastasis, RMH score ≥ 2, higher ECOG PS score and LDH > ULN. Moreover, HPD was correlated with a poor OS and PFS in patients following ICI therapy.
650		4	\|a Immune checkpoint inhibitors (ICIs) \|7 (dpeaa)DE-He213
650		4	\|a Hyperprogressive disease (HPD) \|7 (dpeaa)DE-He213
650		4	\|a Predictors \|7 (dpeaa)DE-He213
650		4	\|a Survival analysis \|7 (dpeaa)DE-He213
700	1		\|a Wu, Q. \|e verfasserin \|4 aut
700	1		\|a Wu, S. \|e verfasserin \|4 aut
700	1		\|a Xie, X. \|e verfasserin \|4 aut
773	0	8	\|i Enthalten in \|t Revista de oncología \|d Barcelona : Doyma, 2000 \|g 23(2021), 9 vom: 13. Apr., Seite 1782-1793 \|w (DE-627)385985452 \|w (DE-600)2143451-7 \|x 1578-195X \|7 nnns
773	1	8	\|g volume:23 \|g year:2021 \|g number:9 \|g day:13 \|g month:04 \|g pages:1782-1793
856	4	0	\|u https://dx.doi.org/10.1007/s12094-021-02579-9 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_105
912			\|a GBV_ILN_120
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_171
912			\|a GBV_ILN_187
912			\|a GBV_ILN_224
912			\|a GBV_ILN_250
912			\|a GBV_ILN_281
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_702
951			\|a AR
952			\|d 23 \|j 2021 \|e 9 \|b 13 \|c 04 \|h 1782-1793

Indexfelder

author_variant	j l jl q w qw s w sw x x xx
matchkey_str	article:1578195X:2021----::netgtooptnilimresfyeporsieieshdrgeebi
hierarchy_sort_str	2021
publishDate	2021
allfields	10.1007/s12094-021-02579-9 doi (DE-627)SPR044656297 (SPR)s12094-021-02579-9-e DE-627 ger DE-627 rakwb eng 610 ASE Liu, J. verfasserin aut Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs) 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Federación de Sociedades Españolas de Oncología (FESEO) 2021 Purpose This project aimed to survey the clinical characteristics and survivals of hyperprogressive disease (HPD) mediated by immune checkpoint inhibitors (ICIs) in an attempt to explore the potential predictors. Methods After searching PubMed, MEDLINE, Google Scholar and Cochrane Library databases, 12 studies incorporating 1766 individuals were enrolled. The data were analyzed with Review manager 5.3 software. Results The results revealed HPD correlated with previous metastatic sites > 2 (OR = 1.86, 95% CI 1.33–2.59, P = 0.0003), liver metastasis (OR = 3.35, 95% CI 2.09–5.35, P < 0.00001), Royal Marsden Hospital (RMH) score ≥ 2 (OR = 2.80, 95% CI 1.85–4.23, P < 0.00001), higher ECOG PS (OR = 1.60, 95% CI 1.13–2.27, P = 0.008) and LDH > upper limits of normal (ULN) (OR = 2.32, 95% CI 1.51–3.58, P = 0.0001). Instead, HPD was unrelated to gender, age, smoking status, PD-L1 expression, therapy, neutrophil-to-lymphocyte ratio, the histology, the status of EGFR, ALK and KRAS in non-small cell lung cancer and HER-2 expression in advanced gastric cancer. Moreover, HPD was evidently correlated with a shorter OS (HR = 2.92, 95% CI 1.79–4.76, P < 0.0001) and PFS (HR = 3.62, 95% CI 2.79–4.68, P < 0.00001). The same phenomena existed in stratified studies based on study regions and tumor types. Conclusions This study demonstrated that HPD was related to the number of prior metastatic sites > 2, liver metastasis, RMH score ≥ 2, higher ECOG PS score and LDH > ULN. Moreover, HPD was correlated with a poor OS and PFS in patients following ICI therapy. Immune checkpoint inhibitors (ICIs) (dpeaa)DE-He213 Hyperprogressive disease (HPD) (dpeaa)DE-He213 Predictors (dpeaa)DE-He213 Survival analysis (dpeaa)DE-He213 Wu, Q. verfasserin aut Wu, S. verfasserin aut Xie, X. verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 23(2021), 9 vom: 13. Apr., Seite 1782-1793 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:23 year:2021 number:9 day:13 month:04 pages:1782-1793 https://dx.doi.org/10.1007/s12094-021-02579-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 23 2021 9 13 04 1782-1793
spelling	10.1007/s12094-021-02579-9 doi (DE-627)SPR044656297 (SPR)s12094-021-02579-9-e DE-627 ger DE-627 rakwb eng 610 ASE Liu, J. verfasserin aut Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs) 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Federación de Sociedades Españolas de Oncología (FESEO) 2021 Purpose This project aimed to survey the clinical characteristics and survivals of hyperprogressive disease (HPD) mediated by immune checkpoint inhibitors (ICIs) in an attempt to explore the potential predictors. Methods After searching PubMed, MEDLINE, Google Scholar and Cochrane Library databases, 12 studies incorporating 1766 individuals were enrolled. The data were analyzed with Review manager 5.3 software. Results The results revealed HPD correlated with previous metastatic sites > 2 (OR = 1.86, 95% CI 1.33–2.59, P = 0.0003), liver metastasis (OR = 3.35, 95% CI 2.09–5.35, P < 0.00001), Royal Marsden Hospital (RMH) score ≥ 2 (OR = 2.80, 95% CI 1.85–4.23, P < 0.00001), higher ECOG PS (OR = 1.60, 95% CI 1.13–2.27, P = 0.008) and LDH > upper limits of normal (ULN) (OR = 2.32, 95% CI 1.51–3.58, P = 0.0001). Instead, HPD was unrelated to gender, age, smoking status, PD-L1 expression, therapy, neutrophil-to-lymphocyte ratio, the histology, the status of EGFR, ALK and KRAS in non-small cell lung cancer and HER-2 expression in advanced gastric cancer. Moreover, HPD was evidently correlated with a shorter OS (HR = 2.92, 95% CI 1.79–4.76, P < 0.0001) and PFS (HR = 3.62, 95% CI 2.79–4.68, P < 0.00001). The same phenomena existed in stratified studies based on study regions and tumor types. Conclusions This study demonstrated that HPD was related to the number of prior metastatic sites > 2, liver metastasis, RMH score ≥ 2, higher ECOG PS score and LDH > ULN. Moreover, HPD was correlated with a poor OS and PFS in patients following ICI therapy. Immune checkpoint inhibitors (ICIs) (dpeaa)DE-He213 Hyperprogressive disease (HPD) (dpeaa)DE-He213 Predictors (dpeaa)DE-He213 Survival analysis (dpeaa)DE-He213 Wu, Q. verfasserin aut Wu, S. verfasserin aut Xie, X. verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 23(2021), 9 vom: 13. Apr., Seite 1782-1793 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:23 year:2021 number:9 day:13 month:04 pages:1782-1793 https://dx.doi.org/10.1007/s12094-021-02579-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 23 2021 9 13 04 1782-1793
allfields_unstemmed	10.1007/s12094-021-02579-9 doi (DE-627)SPR044656297 (SPR)s12094-021-02579-9-e DE-627 ger DE-627 rakwb eng 610 ASE Liu, J. verfasserin aut Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs) 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Federación de Sociedades Españolas de Oncología (FESEO) 2021 Purpose This project aimed to survey the clinical characteristics and survivals of hyperprogressive disease (HPD) mediated by immune checkpoint inhibitors (ICIs) in an attempt to explore the potential predictors. Methods After searching PubMed, MEDLINE, Google Scholar and Cochrane Library databases, 12 studies incorporating 1766 individuals were enrolled. The data were analyzed with Review manager 5.3 software. Results The results revealed HPD correlated with previous metastatic sites > 2 (OR = 1.86, 95% CI 1.33–2.59, P = 0.0003), liver metastasis (OR = 3.35, 95% CI 2.09–5.35, P < 0.00001), Royal Marsden Hospital (RMH) score ≥ 2 (OR = 2.80, 95% CI 1.85–4.23, P < 0.00001), higher ECOG PS (OR = 1.60, 95% CI 1.13–2.27, P = 0.008) and LDH > upper limits of normal (ULN) (OR = 2.32, 95% CI 1.51–3.58, P = 0.0001). Instead, HPD was unrelated to gender, age, smoking status, PD-L1 expression, therapy, neutrophil-to-lymphocyte ratio, the histology, the status of EGFR, ALK and KRAS in non-small cell lung cancer and HER-2 expression in advanced gastric cancer. Moreover, HPD was evidently correlated with a shorter OS (HR = 2.92, 95% CI 1.79–4.76, P < 0.0001) and PFS (HR = 3.62, 95% CI 2.79–4.68, P < 0.00001). The same phenomena existed in stratified studies based on study regions and tumor types. Conclusions This study demonstrated that HPD was related to the number of prior metastatic sites > 2, liver metastasis, RMH score ≥ 2, higher ECOG PS score and LDH > ULN. Moreover, HPD was correlated with a poor OS and PFS in patients following ICI therapy. Immune checkpoint inhibitors (ICIs) (dpeaa)DE-He213 Hyperprogressive disease (HPD) (dpeaa)DE-He213 Predictors (dpeaa)DE-He213 Survival analysis (dpeaa)DE-He213 Wu, Q. verfasserin aut Wu, S. verfasserin aut Xie, X. verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 23(2021), 9 vom: 13. Apr., Seite 1782-1793 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:23 year:2021 number:9 day:13 month:04 pages:1782-1793 https://dx.doi.org/10.1007/s12094-021-02579-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 23 2021 9 13 04 1782-1793
allfieldsGer	10.1007/s12094-021-02579-9 doi (DE-627)SPR044656297 (SPR)s12094-021-02579-9-e DE-627 ger DE-627 rakwb eng 610 ASE Liu, J. verfasserin aut Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs) 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Federación de Sociedades Españolas de Oncología (FESEO) 2021 Purpose This project aimed to survey the clinical characteristics and survivals of hyperprogressive disease (HPD) mediated by immune checkpoint inhibitors (ICIs) in an attempt to explore the potential predictors. Methods After searching PubMed, MEDLINE, Google Scholar and Cochrane Library databases, 12 studies incorporating 1766 individuals were enrolled. The data were analyzed with Review manager 5.3 software. Results The results revealed HPD correlated with previous metastatic sites > 2 (OR = 1.86, 95% CI 1.33–2.59, P = 0.0003), liver metastasis (OR = 3.35, 95% CI 2.09–5.35, P < 0.00001), Royal Marsden Hospital (RMH) score ≥ 2 (OR = 2.80, 95% CI 1.85–4.23, P < 0.00001), higher ECOG PS (OR = 1.60, 95% CI 1.13–2.27, P = 0.008) and LDH > upper limits of normal (ULN) (OR = 2.32, 95% CI 1.51–3.58, P = 0.0001). Instead, HPD was unrelated to gender, age, smoking status, PD-L1 expression, therapy, neutrophil-to-lymphocyte ratio, the histology, the status of EGFR, ALK and KRAS in non-small cell lung cancer and HER-2 expression in advanced gastric cancer. Moreover, HPD was evidently correlated with a shorter OS (HR = 2.92, 95% CI 1.79–4.76, P < 0.0001) and PFS (HR = 3.62, 95% CI 2.79–4.68, P < 0.00001). The same phenomena existed in stratified studies based on study regions and tumor types. Conclusions This study demonstrated that HPD was related to the number of prior metastatic sites > 2, liver metastasis, RMH score ≥ 2, higher ECOG PS score and LDH > ULN. Moreover, HPD was correlated with a poor OS and PFS in patients following ICI therapy. Immune checkpoint inhibitors (ICIs) (dpeaa)DE-He213 Hyperprogressive disease (HPD) (dpeaa)DE-He213 Predictors (dpeaa)DE-He213 Survival analysis (dpeaa)DE-He213 Wu, Q. verfasserin aut Wu, S. verfasserin aut Xie, X. verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 23(2021), 9 vom: 13. Apr., Seite 1782-1793 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:23 year:2021 number:9 day:13 month:04 pages:1782-1793 https://dx.doi.org/10.1007/s12094-021-02579-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 23 2021 9 13 04 1782-1793
allfieldsSound	10.1007/s12094-021-02579-9 doi (DE-627)SPR044656297 (SPR)s12094-021-02579-9-e DE-627 ger DE-627 rakwb eng 610 ASE Liu, J. verfasserin aut Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs) 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Federación de Sociedades Españolas de Oncología (FESEO) 2021 Purpose This project aimed to survey the clinical characteristics and survivals of hyperprogressive disease (HPD) mediated by immune checkpoint inhibitors (ICIs) in an attempt to explore the potential predictors. Methods After searching PubMed, MEDLINE, Google Scholar and Cochrane Library databases, 12 studies incorporating 1766 individuals were enrolled. The data were analyzed with Review manager 5.3 software. Results The results revealed HPD correlated with previous metastatic sites > 2 (OR = 1.86, 95% CI 1.33–2.59, P = 0.0003), liver metastasis (OR = 3.35, 95% CI 2.09–5.35, P < 0.00001), Royal Marsden Hospital (RMH) score ≥ 2 (OR = 2.80, 95% CI 1.85–4.23, P < 0.00001), higher ECOG PS (OR = 1.60, 95% CI 1.13–2.27, P = 0.008) and LDH > upper limits of normal (ULN) (OR = 2.32, 95% CI 1.51–3.58, P = 0.0001). Instead, HPD was unrelated to gender, age, smoking status, PD-L1 expression, therapy, neutrophil-to-lymphocyte ratio, the histology, the status of EGFR, ALK and KRAS in non-small cell lung cancer and HER-2 expression in advanced gastric cancer. Moreover, HPD was evidently correlated with a shorter OS (HR = 2.92, 95% CI 1.79–4.76, P < 0.0001) and PFS (HR = 3.62, 95% CI 2.79–4.68, P < 0.00001). The same phenomena existed in stratified studies based on study regions and tumor types. Conclusions This study demonstrated that HPD was related to the number of prior metastatic sites > 2, liver metastasis, RMH score ≥ 2, higher ECOG PS score and LDH > ULN. Moreover, HPD was correlated with a poor OS and PFS in patients following ICI therapy. Immune checkpoint inhibitors (ICIs) (dpeaa)DE-He213 Hyperprogressive disease (HPD) (dpeaa)DE-He213 Predictors (dpeaa)DE-He213 Survival analysis (dpeaa)DE-He213 Wu, Q. verfasserin aut Wu, S. verfasserin aut Xie, X. verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 23(2021), 9 vom: 13. Apr., Seite 1782-1793 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:23 year:2021 number:9 day:13 month:04 pages:1782-1793 https://dx.doi.org/10.1007/s12094-021-02579-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 23 2021 9 13 04 1782-1793
language	English
source	Enthalten in Revista de oncología 23(2021), 9 vom: 13. Apr., Seite 1782-1793 volume:23 year:2021 number:9 day:13 month:04 pages:1782-1793
sourceStr	Enthalten in Revista de oncología 23(2021), 9 vom: 13. Apr., Seite 1782-1793 volume:23 year:2021 number:9 day:13 month:04 pages:1782-1793
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Immune checkpoint inhibitors (ICIs) Hyperprogressive disease (HPD) Predictors Survival analysis
dewey-raw	610
isfreeaccess_bool	false
container_title	Revista de oncología
authorswithroles_txt_mv	Liu, J. @@aut@@ Wu, Q. @@aut@@ Wu, S. @@aut@@ Xie, X. @@aut@@
publishDateDaySort_date	2021-04-13T00:00:00Z
hierarchy_top_id	385985452
dewey-sort	3610
id	SPR044656297
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR044656297</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519234225.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210725s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12094-021-02579-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR044656297</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12094-021-02579-9-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Liu, J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Federación de Sociedades Españolas de Oncología (FESEO) 2021</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose This project aimed to survey the clinical characteristics and survivals of hyperprogressive disease (HPD) mediated by immune checkpoint inhibitors (ICIs) in an attempt to explore the potential predictors. Methods After searching PubMed, MEDLINE, Google Scholar and Cochrane Library databases, 12 studies incorporating 1766 individuals were enrolled. The data were analyzed with Review manager 5.3 software. Results The results revealed HPD correlated with previous metastatic sites > 2 (OR = 1.86, 95% CI 1.33–2.59, P = 0.0003), liver metastasis (OR = 3.35, 95% CI 2.09–5.35, P < 0.00001), Royal Marsden Hospital (RMH) score ≥ 2 (OR = 2.80, 95% CI 1.85–4.23, P < 0.00001), higher ECOG PS (OR = 1.60, 95% CI 1.13–2.27, P = 0.008) and LDH > upper limits of normal (ULN) (OR = 2.32, 95% CI 1.51–3.58, P = 0.0001). Instead, HPD was unrelated to gender, age, smoking status, PD-L1 expression, therapy, neutrophil-to-lymphocyte ratio, the histology, the status of EGFR, ALK and KRAS in non-small cell lung cancer and HER-2 expression in advanced gastric cancer. Moreover, HPD was evidently correlated with a shorter OS (HR = 2.92, 95% CI 1.79–4.76, P < 0.0001) and PFS (HR = 3.62, 95% CI 2.79–4.68, P < 0.00001). The same phenomena existed in stratified studies based on study regions and tumor types. Conclusions This study demonstrated that HPD was related to the number of prior metastatic sites > 2, liver metastasis, RMH score ≥ 2, higher ECOG PS score and LDH > ULN. Moreover, HPD was correlated with a poor OS and PFS in patients following ICI therapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immune checkpoint inhibitors (ICIs)</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hyperprogressive disease (HPD)</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Predictors</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Survival analysis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wu, Q.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wu, S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xie, X.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Revista de oncología</subfield><subfield code="d">Barcelona : Doyma, 2000</subfield><subfield code="g">23(2021), 9 vom: 13. Apr., Seite 1782-1793</subfield><subfield code="w">(DE-627)385985452</subfield><subfield code="w">(DE-600)2143451-7</subfield><subfield code="x">1578-195X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:23</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:9</subfield><subfield code="g">day:13</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:1782-1793</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12094-021-02579-9</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">23</subfield><subfield code="j">2021</subfield><subfield code="e">9</subfield><subfield code="b">13</subfield><subfield code="c">04</subfield><subfield code="h">1782-1793</subfield></datafield></record></collection>
author	Liu, J.
spellingShingle	Liu, J. ddc 610 misc Immune checkpoint inhibitors (ICIs) misc Hyperprogressive disease (HPD) misc Predictors misc Survival analysis Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs)
authorStr	Liu, J.
ppnlink_with_tag_str_mv	@@773@@(DE-627)385985452
format	electronic Article
dewey-ones	610 - Medicine & health
delete_txt_mv	keep
author_role	aut aut aut aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	1578-195X
topic_title	610 ASE Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs) Immune checkpoint inhibitors (ICIs) (dpeaa)DE-He213 Hyperprogressive disease (HPD) (dpeaa)DE-He213 Predictors (dpeaa)DE-He213 Survival analysis (dpeaa)DE-He213
topic	ddc 610 misc Immune checkpoint inhibitors (ICIs) misc Hyperprogressive disease (HPD) misc Predictors misc Survival analysis
topic_unstemmed	ddc 610 misc Immune checkpoint inhibitors (ICIs) misc Hyperprogressive disease (HPD) misc Predictors misc Survival analysis
topic_browse	ddc 610 misc Immune checkpoint inhibitors (ICIs) misc Hyperprogressive disease (HPD) misc Predictors misc Survival analysis
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Revista de oncología
hierarchy_parent_id	385985452
dewey-tens	610 - Medicine & health
hierarchy_top_title	Revista de oncología
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)385985452 (DE-600)2143451-7
title	Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs)
ctrlnum	(DE-627)SPR044656297 (SPR)s12094-021-02579-9-e
title_full	Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs)
author_sort	Liu, J.
journal	Revista de oncología
journalStr	Revista de oncología
lang_code	eng
isOA_bool	false
dewey-hundreds	600 - Technology
recordtype	marc
publishDateSort	2021
contenttype_str_mv	txt
container_start_page	1782
author_browse	Liu, J. Wu, Q. Wu, S. Xie, X.
container_volume	23
class	610 ASE
format_se	Elektronische Aufsätze
author-letter	Liu, J.
doi_str_mv	10.1007/s12094-021-02579-9
dewey-full	610
author2-role	verfasserin
title_sort	investigation on potential biomarkers of hyperprogressive disease (hpd) triggered by immune checkpoint inhibitors (icis)
title_auth	Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs)
abstract	Purpose This project aimed to survey the clinical characteristics and survivals of hyperprogressive disease (HPD) mediated by immune checkpoint inhibitors (ICIs) in an attempt to explore the potential predictors. Methods After searching PubMed, MEDLINE, Google Scholar and Cochrane Library databases, 12 studies incorporating 1766 individuals were enrolled. The data were analyzed with Review manager 5.3 software. Results The results revealed HPD correlated with previous metastatic sites > 2 (OR = 1.86, 95% CI 1.33–2.59, P = 0.0003), liver metastasis (OR = 3.35, 95% CI 2.09–5.35, P < 0.00001), Royal Marsden Hospital (RMH) score ≥ 2 (OR = 2.80, 95% CI 1.85–4.23, P < 0.00001), higher ECOG PS (OR = 1.60, 95% CI 1.13–2.27, P = 0.008) and LDH > upper limits of normal (ULN) (OR = 2.32, 95% CI 1.51–3.58, P = 0.0001). Instead, HPD was unrelated to gender, age, smoking status, PD-L1 expression, therapy, neutrophil-to-lymphocyte ratio, the histology, the status of EGFR, ALK and KRAS in non-small cell lung cancer and HER-2 expression in advanced gastric cancer. Moreover, HPD was evidently correlated with a shorter OS (HR = 2.92, 95% CI 1.79–4.76, P < 0.0001) and PFS (HR = 3.62, 95% CI 2.79–4.68, P < 0.00001). The same phenomena existed in stratified studies based on study regions and tumor types. Conclusions This study demonstrated that HPD was related to the number of prior metastatic sites > 2, liver metastasis, RMH score ≥ 2, higher ECOG PS score and LDH > ULN. Moreover, HPD was correlated with a poor OS and PFS in patients following ICI therapy. © Federación de Sociedades Españolas de Oncología (FESEO) 2021
abstractGer	Purpose This project aimed to survey the clinical characteristics and survivals of hyperprogressive disease (HPD) mediated by immune checkpoint inhibitors (ICIs) in an attempt to explore the potential predictors. Methods After searching PubMed, MEDLINE, Google Scholar and Cochrane Library databases, 12 studies incorporating 1766 individuals were enrolled. The data were analyzed with Review manager 5.3 software. Results The results revealed HPD correlated with previous metastatic sites > 2 (OR = 1.86, 95% CI 1.33–2.59, P = 0.0003), liver metastasis (OR = 3.35, 95% CI 2.09–5.35, P < 0.00001), Royal Marsden Hospital (RMH) score ≥ 2 (OR = 2.80, 95% CI 1.85–4.23, P < 0.00001), higher ECOG PS (OR = 1.60, 95% CI 1.13–2.27, P = 0.008) and LDH > upper limits of normal (ULN) (OR = 2.32, 95% CI 1.51–3.58, P = 0.0001). Instead, HPD was unrelated to gender, age, smoking status, PD-L1 expression, therapy, neutrophil-to-lymphocyte ratio, the histology, the status of EGFR, ALK and KRAS in non-small cell lung cancer and HER-2 expression in advanced gastric cancer. Moreover, HPD was evidently correlated with a shorter OS (HR = 2.92, 95% CI 1.79–4.76, P < 0.0001) and PFS (HR = 3.62, 95% CI 2.79–4.68, P < 0.00001). The same phenomena existed in stratified studies based on study regions and tumor types. Conclusions This study demonstrated that HPD was related to the number of prior metastatic sites > 2, liver metastasis, RMH score ≥ 2, higher ECOG PS score and LDH > ULN. Moreover, HPD was correlated with a poor OS and PFS in patients following ICI therapy. © Federación de Sociedades Españolas de Oncología (FESEO) 2021
abstract_unstemmed	Purpose This project aimed to survey the clinical characteristics and survivals of hyperprogressive disease (HPD) mediated by immune checkpoint inhibitors (ICIs) in an attempt to explore the potential predictors. Methods After searching PubMed, MEDLINE, Google Scholar and Cochrane Library databases, 12 studies incorporating 1766 individuals were enrolled. The data were analyzed with Review manager 5.3 software. Results The results revealed HPD correlated with previous metastatic sites > 2 (OR = 1.86, 95% CI 1.33–2.59, P = 0.0003), liver metastasis (OR = 3.35, 95% CI 2.09–5.35, P < 0.00001), Royal Marsden Hospital (RMH) score ≥ 2 (OR = 2.80, 95% CI 1.85–4.23, P < 0.00001), higher ECOG PS (OR = 1.60, 95% CI 1.13–2.27, P = 0.008) and LDH > upper limits of normal (ULN) (OR = 2.32, 95% CI 1.51–3.58, P = 0.0001). Instead, HPD was unrelated to gender, age, smoking status, PD-L1 expression, therapy, neutrophil-to-lymphocyte ratio, the histology, the status of EGFR, ALK and KRAS in non-small cell lung cancer and HER-2 expression in advanced gastric cancer. Moreover, HPD was evidently correlated with a shorter OS (HR = 2.92, 95% CI 1.79–4.76, P < 0.0001) and PFS (HR = 3.62, 95% CI 2.79–4.68, P < 0.00001). The same phenomena existed in stratified studies based on study regions and tumor types. Conclusions This study demonstrated that HPD was related to the number of prior metastatic sites > 2, liver metastasis, RMH score ≥ 2, higher ECOG PS score and LDH > ULN. Moreover, HPD was correlated with a poor OS and PFS in patients following ICI therapy. © Federación de Sociedades Españolas de Oncología (FESEO) 2021
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702
container_issue	9
title_short	Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs)
url	https://dx.doi.org/10.1007/s12094-021-02579-9
remote_bool	true
author2	Wu, Q. Wu, S. Xie, X.
author2Str	Wu, Q. Wu, S. Xie, X.
ppnlink	385985452
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.1007/s12094-021-02579-9
up_date	2024-07-04T01:45:23.020Z
_version_	1803611037260316672
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR044656297</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519234225.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210725s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12094-021-02579-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR044656297</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12094-021-02579-9-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Liu, J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Federación de Sociedades Españolas de Oncología (FESEO) 2021</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose This project aimed to survey the clinical characteristics and survivals of hyperprogressive disease (HPD) mediated by immune checkpoint inhibitors (ICIs) in an attempt to explore the potential predictors. Methods After searching PubMed, MEDLINE, Google Scholar and Cochrane Library databases, 12 studies incorporating 1766 individuals were enrolled. The data were analyzed with Review manager 5.3 software. Results The results revealed HPD correlated with previous metastatic sites > 2 (OR = 1.86, 95% CI 1.33–2.59, P = 0.0003), liver metastasis (OR = 3.35, 95% CI 2.09–5.35, P < 0.00001), Royal Marsden Hospital (RMH) score ≥ 2 (OR = 2.80, 95% CI 1.85–4.23, P < 0.00001), higher ECOG PS (OR = 1.60, 95% CI 1.13–2.27, P = 0.008) and LDH > upper limits of normal (ULN) (OR = 2.32, 95% CI 1.51–3.58, P = 0.0001). Instead, HPD was unrelated to gender, age, smoking status, PD-L1 expression, therapy, neutrophil-to-lymphocyte ratio, the histology, the status of EGFR, ALK and KRAS in non-small cell lung cancer and HER-2 expression in advanced gastric cancer. Moreover, HPD was evidently correlated with a shorter OS (HR = 2.92, 95% CI 1.79–4.76, P < 0.0001) and PFS (HR = 3.62, 95% CI 2.79–4.68, P < 0.00001). The same phenomena existed in stratified studies based on study regions and tumor types. Conclusions This study demonstrated that HPD was related to the number of prior metastatic sites > 2, liver metastasis, RMH score ≥ 2, higher ECOG PS score and LDH > ULN. Moreover, HPD was correlated with a poor OS and PFS in patients following ICI therapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immune checkpoint inhibitors (ICIs)</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hyperprogressive disease (HPD)</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Predictors</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Survival analysis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wu, Q.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wu, S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xie, X.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Revista de oncología</subfield><subfield code="d">Barcelona : Doyma, 2000</subfield><subfield code="g">23(2021), 9 vom: 13. Apr., Seite 1782-1793</subfield><subfield code="w">(DE-627)385985452</subfield><subfield code="w">(DE-600)2143451-7</subfield><subfield code="x">1578-195X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:23</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:9</subfield><subfield code="g">day:13</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:1782-1793</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12094-021-02579-9</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">23</subfield><subfield code="j">2021</subfield><subfield code="e">9</subfield><subfield code="b">13</subfield><subfield code="c">04</subfield><subfield code="h">1782-1793</subfield></datafield></record></collection>
score	7.400319

Nicht das Richtige dabei?

Schreiben Sie uns!

Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs)

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?